Siva Brian, Hawley Carmel M, McDonald Stephen P, Brown Fiona G, Rosman Johan B, Wiggins Kathryn J, Bannister Kym M, Johnson David W
Australia and New Zealand Dialysis and Transplant Registry, University of Adelaide at Queen Elizabeth Hospital, Adelaide, South Australia, Australia.
Clin J Am Soc Nephrol. 2009 May;4(5):957-64. doi: 10.2215/CJN.00010109. Epub 2009 Apr 30.
Pseudomonas peritonitis is a serious complication of peritoneal dialysis. To date, there as been no comprehensive, multicenter study of this condition.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The predictors, treatment, and clinical outcomes of Pseudomonas peritonitis were examined by binary logistic regression and multilevel, multivariate Poisson regression in all Australian PD patients in 66 centers between 2003 and 2006.
A total of 191 episodes of Pseudomonas peritonitis (5.3% of all peritonitis episodes) occurred in 171 individuals. Its occurrence was independently predicted by Maori/Pacific Islander race, Aboriginal/Torres Strait Islander race, and absence of baseline peritoneal equilibration test data. Compared with other organisms, Pseudomonas peritonitis was associated with greater frequencies of hospitalization (96 versus 79%; P = 0.006), catheter removal (44 versus 20%; P < 0.001), and permanent hemodialysis transfer (35 versus 17%; P < 0.001) but comparable death rates (3 versus 2%; P = 0.4). Initial empiric antibiotic choice did not influence outcomes, but subsequent use of dual anti-pseudomonal therapy was associated with a lower risk for permanent hemodialysis transfer (10 versus 38%, respectively; P = 0.03). Catheter removal was associated with a lower risk for death than treatment with antibiotics alone (0 versus 6%; P < 0.05).
Pseudomonas peritonitis is associated with high rates of catheter removal and permanent hemodialysis transfer. Prompt catheter removal and use of two anti-pseudomonal antibiotics are associated with better outcomes.
铜绿假单胞菌腹膜炎是腹膜透析的一种严重并发症。迄今为止,尚无针对该病症的全面、多中心研究。
设计、地点、参与者及测量方法:通过二元逻辑回归以及多水平、多变量泊松回归,对2003年至2006年间澳大利亚66个中心的所有腹膜透析患者的铜绿假单胞菌腹膜炎的预测因素、治疗方法及临床结果进行了研究。
171名患者共发生了191次铜绿假单胞菌腹膜炎发作(占所有腹膜炎发作的5.3%)。毛利/太平洋岛民种族、原住民/托雷斯海峡岛民种族以及缺乏基线腹膜平衡试验数据可独立预测其发生。与其他微生物相比,铜绿假单胞菌腹膜炎患者的住院频率更高(96%对79%;P = 0.006)、拔除导管的频率更高(44%对20%;P < 0.001)以及转为永久性血液透析的频率更高(35%对17%;P < 0.001),但死亡率相当(3%对2%;P = 0.4)。初始经验性抗生素选择并不影响治疗结果,但随后使用双联抗铜绿假单胞菌治疗可降低转为永久性血液透析的风险(分别为10%对38%;P = 0.03)。与单纯使用抗生素治疗相比,拔除导管与更低的死亡风险相关(0%对6%;P < 0.05)。
铜绿假单胞菌腹膜炎与高拔除导管率和高转为永久性血液透析率相关。及时拔除导管和使用两种抗铜绿假单胞菌抗生素与更好的治疗结果相关。